GLP-1 RA use was evaluated for fragility fracture risk in older adults with T2D, providing important safety data for a population at elevated fracture risk due to both age and diabetes.
Bones in the balanceOlder diabetic patients on GLP-1 drugs face competing concerns: metabolic benefits from weight loss vs potential bone weakening — fracture risk data is essential
What the researchers found
GLP-1 RA fracture risk evaluated in older T2D adults, providing important safety data for this high-fracture-risk population experiencing significant drug-induced weight loss.
Why it matters
Falls and fractures are leading causes of disability and death in older adults. Knowing if GLP-1 drugs affect bone health is critical for this population.
How the study worked
Study evaluating fragility fracture risk associated with GLP-1 RA use in older adults with T2D.
What this study cannot tell us
Observational. Fracture risk influenced by many factors beyond drug therapy.
How to read the evidence
Safety evaluation in a high-risk population.
When this study was published
Published in 2025.
The bigger picture
As GLP-1 drugs are prescribed to older patients, bone safety becomes a key consideration alongside metabolic benefits.
Questions still open
- Should bone density monitoring accompany GLP-1 therapy in elderly?
- Does exercise during GLP-1 therapy protect bone?
- Are some GLP-1 drugs safer for bones than others?
Common questions
Do GLP-1 drugs increase fracture risk in older people?
Should older patients avoid GLP-1 drugs?
Read the original research
GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes.
The Journal of clinical endocrinology and metabolism
Citation
Kasher Meron, Michal; Hornik-Lurie, Tzipi; Twig, Gilad; Rotman-Pikielny, Pnina. (2026). GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes.. The Journal of clinical endocrinology and metabolism. https://doi.org/10.1210/clinem/dgag056